Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (NASDAQ:PSTV) presented positive data from their CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 SNO/ASCO CNS Metastases Conference. The retrospective analysis, involving 613 CNSide assays from 218 patients across 5 institutions, demonstrated significant capabilities in detecting and monitoring leptomeningeal metastases (LM).
Key findings include 67% detection rate of CSF tumor cells, with notable observations of immunocytochemistry and FISH probe detection changes in patients with multiple CSF draws. The platform showed 2.8 times higher diagnostic sensitivity compared to standard CSF cytology and influenced clinical management decisions in over 90% of LM cases.
Plus Therapeutics (NASDAQ:PSTV) announced the commercial launch of its CNSide® diagnostic platform in Texas starting August 2025. The CNSide cerebrospinal fluid assay platform will initially focus on NCI-Designated Cancer Centers, including UT Southwestern, MD Anderson Cancer Center, and other major healthcare systems.
The CNSide platform is designed to identify tumor cells that have metastasized to the central nervous system, demonstrating 92% sensitivity and 95% specificity. The diagnostic tool has influenced treatment decisions in over 90% of cases and has been validated through more than 11,000 tests performed at over 200 U.S. cancer institutions since 2020.
Plus Therapeutics (NASDAQ:PSTV) has received a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded $17.6 million grant. The company expects an additional $6 million in funding over the next 12 months.
The non-dilutive financing will support the clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial and the development of CNSide LM diagnostic test. CPRIT, the second-largest public cancer research funder globally, along with active NIH and DoD grants, demonstrates strong institutional support for Plus Therapeutics' clinical programs.
Plus Therapeutics (NASDAQ:PSTV) announced it will present final results from its ReSPECT-LM clinical trial for REYOBIQ™ in treating leptomeningeal metastases (LM) at the 2025 SNO/ASCO CNS Metastases Conference. The presentation will be delivered by Dr. Andrew Brenner on August 15, 2025, focusing on Phase 1 dose escalation study results for safety and efficacy.
The company will also host an educational symposium titled "Reimagining Your Approach to Leptomeningeal Metastases" on August 14, featuring presentations from five leading neuro-oncologists. Previously reported data showed encouraging safety profiles and response signals in LM patients. Additionally, Plus Therapeutics' subsidiary, CNSide Diagnostics, will present two separate presentations at the conference.
Plus Therapeutics (NASDAQ:PSTV) announced two upcoming presentations featuring its CNSide Cerebrospinal Fluid (CSF) Assay Platform at the SNO/ASCO CNS Metastases Conference, scheduled for August 14-16, 2025, in Baltimore, MD.
The presentations, both delivered by Dr. Priya Kumthekar, will focus on CSF tumor cell detection and quantification in patients with leptomeningeal disease. The diagnostic platform's capabilities in enhancing CNS metastases management and supporting therapies like REYOBIQ™ in the ReSPECT-LM dose optimization trial will be highlighted.
Plus Therapeutics (NASDAQ:PSTV) has announced the successful treatment of initial patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) targeting leptomeningeal metastases (LM). The trial follows promising Phase 1 results where 5 out of 7 patients achieved over 80% reduction in LM tumor cells and survived at least one year post-treatment.
The dose optimization study, supported by a $17.6 million CPRIT grant, aims to determine optimal dosing for efficacy and safety in alignment with FDA's Project Optimus. The company expects to complete Cohort 1 enrollment by year-end and plans to present additional Phase 1 data at the SNO/ASCO CNS Metastases Conference in August 2025.
Plus Therapeutics (NASDAQ:PSTV) has announced FDA agreement to initiate the ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) in treating leptomeningeal metastases (LM). The trial, supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas, builds upon promising results from their completed Phase 1 trial.
The dose optimization study will enroll up to 24 patients across four cohorts, evaluating multiple-dose regimens of REYOBIQ at the recommended Phase 2 dose of 44.1 mCi. The trial will be conducted at two Texas cancer centers: the University of Texas Health Science Center at San Antonio and the University of Texas Southwestern Medical Center.
The completed Phase 1 trial demonstrated encouraging results, including a 76% clinical benefit rate in neuroimaging results, with 29% achieving partial responses and 47% maintaining stable disease. Notably, 5 of 7 patients with over 80% reduction of LM tumor cells in CSF survived at least one year after initial treatment.
Plus Therapeutics (NASDAQ:PSTV) announced a business update for its CNSide Diagnostics subsidiary, which is preparing for the U.S. commercial launch of its novel CNS cancer diagnostic platform in H2 2025. The CNSide CSF Assay Platform, acquired in 2024, addresses an estimated $6 billion U.S. market opportunity for central nervous system cancer metastases diagnosis.
The platform has demonstrated 92% sensitivity and 95% specificity, with over 11,000 tests performed at 200+ U.S. cancer institutions since 2020. The company has established a testing laboratory in Houston, TX, and plans to launch first in Texas before expanding to other states. While the launch is on track for 2025, meaningful revenue contributions are expected in fiscal year 2026.
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will host a business update conference call on Thursday, June 26, 2025, at 9:00 AM ET.
The company will release its business update before market open, followed by a conference call and webcast where management will provide additional details. Participants are encouraged to pre-register through the provided dial-in link, and should join 15 minutes before the start time. A replay will be available on the company's website for 90 days following the live call.
Plus Therapeutics (NASDAQ:PSTV) has received FDA clearance for its Investigational New Drug (IND) application for REYOBIQ™, targeting pediatric brain cancers. The Phase 1/2a clinical trial, supported by a $3.0 million Department of Defense grant, will focus on treating children with high-grade glioma (HGG) and ependymoma.
The trial consists of two parts: a Phase 1a/b dose escalation study enrolling approximately 24 patients to determine maximum tolerated dose, and a Phase 2a efficacy study with 32 patients. REYOBIQ delivers targeted beta radiation directly to brain tumors while minimizing damage to healthy tissue. The therapy builds on promising results from the adult recurrent glioblastoma trial, which showed doubled overall survival in patients receiving therapeutic radiation doses.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
